Top Executives

J. Mark Lievonen, C.M., FCPA, FCA

Mark Lievonen is President of Sanofi Pasteur Limited, the Canadian vaccine division of Sanofi.  Under his leadership, Sanofi Pasteur has become a billion dollar enterprise in Canada, manufacturing over 50 million doses of vaccines for both domestic and international markets.

Mr. Lievonen is a Director of Oncolytics Biotech Inc., past Chair and Board Member, Canada’s Research-Based Pharmaceutical Companies (Rx&D), Vice-Chair of the Ontario Institute for Cancer Research, and serves on the Boards of the Public Policy Forum and BIOTECanada.

He is a past Chair of the Ontario Genomics Institute, BIOTECanada, the Markham Stouffville Hospital Foundation, the Centre for the Advancement of Health Innovations and the Steering Committee for the BIO 2002 International Conference.   He served on the York University Board of Governors and the Markham Stouffville Hospital Foundation Board, and is a former director of Markham Stouffville Hospital and YORKbiotech.

Mr. Lievonen was a Co-Chair of the Ontario-Quebec Private Sector Advisory Committee and was a member of the Ontario Investment and Trade Advisory Council, the BIOCouncil, and the Toronto Mayor’s Economic Competitiveness Advisory Committee. He served as a member of the United Way of Greater Toronto Cabinet, chairing the Health Care Division. 

He holds a BBA in accounting and an MBA in finance and marketing from the Schulich School of Business, York University. He is a Chartered Accountant and received his designation while working with PricewaterhouseCoopers.

Mr. Lievonen was the recipient of a Queen’s Golden Jubilee Medallion in 2002, was named a Chevalier de l'Ordre National de Mérite by the government of France in 2007 and received the Queen’s Diamond Jubilee Medal in 2012.  He was elected a Fellow of the Institute of Chartered Accountants of Ontario in 2009 and was inducted into the Canadian Healthcare Marketing Hall of Fame in 2013.  In 2014 Mr. Lievonen received the Life Sciences Ontario Lifetime Achievement Award.  In June 2015 he received an Honorary Doctor of Laws degree from York University. On July 1, 2015, Mr. Lievonen was appointed to the Order of Canada. In November 2015 he received an Honorary Life Achievement designation from Canada’s Research-Based Pharmaceutical Companies (Rx&D).

November 2015